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Agonist and antagonist effects of
tobacco-related nitrosamines on
human α4β2 nicotinic acetylcholine
receptors
Simone Brusco, Paola Ambrosi, Simone Meneghini and Andrea Becchetti *
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milano, Italy
Regulation of the “neuronal” nicotinic acetylcholine receptors (nAChRs) is implicated in
both tobacco addiction and smoking-dependent tumor promotion. Some of these effects
are caused by the tobacco-derived N-nitrosamines, which are carcinogenic compounds
that avidly bind to nAChRs. However, the functional effects of these drugs on specific
nAChR subtypes are largely unknown. By using patch-clamp methods, we tested
4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN)
on human α4β2 nAChRs. These latter are widely distributed in the mammalian brain and
are also frequently expressed outside the nervous system. NNK behaved as a partial
agonist, with an apparent EC50 of 16.7µM. At 100µM, it activated 16% of the maximal
current activated by nicotine. When NNK was co-applied with nicotine, it potentiated
the currents elicited by nicotine concentrations ≤100 nM. At higher concentrations of
nicotine, NNK always inhibited the α4β2 nAChR. In contrast, NNN was a pure inhibitor of
this nAChR subtype, with IC50 of approximately 1 nM in the presence of 10µM nicotine.
The effects of both NNK and NNN were mainly competitive and largely independent of
Vm. The different actions of NNN and NNK must be taken into account when interpreting
their biological effects in vitro and in vivo.
Keywords: CHRNA4, CHRNB2, HEK, nAChR, NNK, NNN, partial agonist, patch-clamp
Introduction
The nAChRs are ligand-gated ion channels permeable to cations, which regulate cell excitability
and synaptic transmission. They are formed by different α and β subunits, which assemble to form
homo- or heteropentamers (Dani and Bertrand, 2007). The homopentameric receptors, such as the
widespread (α7)5, have low sensitivity to ACh and nicotine (with EC50 higher than 100µM), high
permeability to Ca2+ (PCa) and rapid desensitization. The heteromeric nAChRs generally display
higher sensitivity to the agonists, lower PCa and slower desensitization (Dani and Bertrand, 2007).
The most common high-affinity form in the mammalian brain is the α4β2∗, with apparent EC50
values at least 10 times lower than those displayed by (α7)5. In the peripheral nervous system,
Abbreviations: CNS, central nervous system; DHβE, dihydro-β-erythroidine; nAChR, neuronal nicotinic acetylcholine
receptor; EC50high and EC50low, EC50 values for two-term Hill equations; HEK, human embryonic kidney; nH, Hill coefficient
for one-term Hill equation; nH1, nH2, Hill coefficients for two-term Hill equation; NNK, 4-(methylnitrosamine)-1-(3-
pyridyl)-1-butanone; NNN, N′-nitrosonornicotine; Vm, membrane potential; Vrev, reversal potential.
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the prevalent nAChR subtype is α3β4, which shows a more
restricted expression in the CNS (Zoli et al., 2015). Nicotinic
subunits are also widely expressed in other tissues, where their
functions are still debated (Wessler and Kirkpatrick, 2008).
In cancer cells, different types of homo- and heteromeric
nAChRs cooperate in controlling several aspects of the neoplastic
phenotype (Egleton et al., 2008; Schuller, 2009; Ambrosi and
Becchetti, 2013; Schaal and Chellappan, 2014). Recently, the
nAChR genes CHRNA3, CHRNA5, and CHRNB4 have been
implicated in lung cancer susceptibility as well as nicotine
addiction (Improgo et al., 2013, and references therein).
The complex pattern of nAChR expression may partly explain
the pleiotropic effects of smoking. In the brain, uncontrolled
stimulation of nAChRs is thought to mediate the addictive effects
of tobacco (Changeux, 2010). In other tissues, smoking can
produce toxic as well as carcinogenic effects. These latter depend
on long-term exposure to several tobacco metabolites, especially
the N-nitrosamines (here simply referred to as “nitrosamines”;
Hecht and Hoffmann, 1988).Whenmetabolically activated, these
drugs cause DNA mutations, particularly G to T transversions
that may lead to mutation of k-ras and p53 (Pfeifer et al.,
2002). Nonetheless, many harmful effects of the tobacco-
related nitrosamines may be attributed to direct targeting of
nAChRs. In fact, the nitrosamines that produce the most potent
biological effects are structural analogs of either ACh (e.g.,
diethylnitrosamine) or nicotine (especially NNK and NNN;
Figure 1). All of these compounds can bind to nAChRs (Schuller
and Orloff, 1998; Schuller, 2007). Although nicotine is not
carcinogenic, engagement of nAChRs with either nicotine or
nitrosamines can promote the neoplastic progression in cultured
cells, by stimulating cell cycle, migration, angiogenesis, epithelial-
to-mesenchymal transition, and inhibiting apoptosis (Schuller,
1989; Maneckjee and Minna, 1990; Heeschen et al., 2001;
Arredondo et al., 2006; Guo et al., 2008; Paleari et al., 2008;
Song et al., 2008; Al-Wadei and Schuller, 2009; Calleja-Macias
et al., 2009; Dasgupta et al., 2009). Similar evidence is slowly
accumulating in vivo (Heeschen et al., 2001; Paleari et al.,
2009).
The pathophysiological interpretation of these studies
requires to clarify the signaling pathways downstream to nAChR
binding (West et al., 2003; Tsurutani et al., 2005; Guo et al., 2008;
Ambrosi and Becchetti, 2013). However, a general hindrance
to full comprehension of the cellular effects of nitrosamines is
that the direct functional action of these drugs on nAChRs is
largely unknown. The only such study currently available shows
that NNN inhibits α3β4 nAChR at high concentrations (IC50
was 1.14mM, in the presence of 100µM nicotine), whereas it
exerts little effect on the muscle subtype (Nunes-Alves et al.,
2012). The lack of direct functional tests is a major lacuna,
as binding studies alone cannot distinguish whether a certain
compound directly activates or inhibits nAChRs, nor the
related kinetics. Moreover, the downstream cell signals could be
regulated by conductive as well as non-conductive mechanisms
(Becchetti, 2011). Understanding the functional interplay
between nitrosamines and ACh or nicotine is also necessary
to interpret their effects in the brain. Smokers are exposed
to a mixture of tobacco-related nAChR ligands. Compounds
FIGURE 1 | Molecular structures of nicotine, NNK, and NNN. NNN and
NNK are the two most potent carcinogenic N-nitrosamines. They derive from
nitrosation of nicotine, which occurs during tobacco treatment and storage as
well as through metabolic processing in mammals.
such as NNK easily traverse the blood brain barrier (Jorquera
et al., 1992; Gerde et al., 1998; Berridge et al., 2010) and have
been found to activate microglia in vivo (Ghosh et al., 2009).
These molecules are likely to interfere with one another and
with the physiological agonist, to alter synaptic transmission
and regulate tobacco addiction in currently unpredictable
ways.
We studied by patch-clamp methods the effect of NNK and
NNN on human α4β2 nAChRs stably expressed in HEK cells.
This nAChR subtype is widely distributed in the brain, where it
regulates both excitatory and inhibitory transmission (Becchetti
et al., 2015) and is implicated in the cognitive and addictive
effects of smoking (Changeux, 2010; Faure et al., 2014). It is
also commonly expressed in non-nervous tissue, including lung
cells (Fu et al., 2009), and tumor cell lines (Egleton et al., 2008).
We found that these nitrosamines exert distinct actions, as NNK
is a partial agonist, whereas NNN is a pure inhibitor of α4β2
nAChRs.
Materials and Methods
Cell Cultures
HEK 293 cells stably expressing human α4β2 nAChRs were
cultured by standard methods (Di Resta et al., 2010). In brief,
cultures were maintained in Dulbecco’s modified Eagle’s medium
(Hyclone Laboratories), supplemented with 10% fetal calf serum
(Hyclone), 4.5 g/l glutamine, 0.05 ng/ml hygromycin β, and
0.25µg/ml amphoterycin B. Cells were grown at 37◦C and
5% CO2. For patch-clamp experiments, cells were harvested
by treatment with trypsin and plated onto 35mm Petri dishes
(Corning Inc.).
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Patch-clamp Recording
Cells were voltage-clamped by using the whole-cell configuration
of the patch-clamp method. Currents were registered with
an Axopatch 200B amplifier (Molecular Devices), at room
temperature (20–22◦C). Micropipettes (3–4 M) were
pulled from borosilicate capillaries (GMBH) with a P-97
Flaming/Brown Micropipette Puller (Sutter Instrument Co.).
The cell capacitance and series resistance (up to about 75%)
were always compensated. Currents were low-pass filtered
at 2 kHz and acquired on-line at 5–10 kHz with Molecular
Devices hardware and software (pClamp 8 and Axoscope 8).
After patch rupture, we usually allowed 1–2min for pipette
solution exchange and signal stabilization, before applying our
stimuli. Extracellular solutions were applied with an RSC-160
Rapid Solution Changer (BioLogic Science Instruments). The
solution is delivered to the cells through borosilicate capillaries
connected to Tygon tubes. Seven independent lines are available.
Each line was generally reserved to one compound at a given
concentration. The perfusing line was totally substituted
whenever the drug was changed. No corrections for leak or
junction potentials was ever applied to any of the displayed
results.
Solutions and Drugs
Unless otherwise indicated, chemicals, and drugs were purchased
by Sigma-Aldrich Italia Srl. The extracellular solution contained
(mM): NaCl 130, KCl 5, CaCl2 2, MgCl2 2, HEPES 10, D-
glucose 5 (pH 7.4; adjusted with NaOH). Pipettes contained
(mM): K-aspartate 120, NaCl 10,MgCl2 2, CaCl21.3, EGTA-KOH
10, HEPES 10, MgATP 1, (pH 7.3; adjusted with KOH). Stock
solutions of nicotine (up to 10mM) were prepared weekly in
our external solution and kept refrigerated. The pH was always
checked after nicotine addition. NNK and NNN (20mM) were
dissolved in water and kept refrigerated for no longer than 1
week. Nicotine and/or nitrosamines were added daily to the
extracellular solution. The final concentrations were obtained by
serial dilution.
Analysis of Data
Data were analyzed with Clampfit 9.2 (Molecular Devices) and
OriginPro 9 (OriginLab Co.). Theoretical curves best fitting
the data were determined by a nonlinear least-squares method
(Levenberg-Marquardt algorithm). For nAChR activation we
used both a simple Hill function and the sum of two Hill
expressions (Covernton and Connolly, 2000). The single-term
expression was:
IL
Imax
=
1
(1+ EC50[L] )
nH
(1)
where Imaxis the maximal current, IL is the peak current at a
given concentration of agonist L, EC50 is the concentration of L
at which IL/Imax = 0.5, and nH is the Hill coefficient.
The two-terms Hill expression was:
IL
Imax
=
A
(1+
EC50high
[L] )
nH1
+
1− A
(1+
EC50low
[L] )
nH2
(2)
where A is the fraction of receptors in the high-affinity state;
EC50high and EC50low are the EC50 values of the components
at high and low affinity, respectively; nH1 and nH2 are the
corresponding Hill coefficients, and the other symbols are as in
Equation (1).
The function used to fit the desensitization data points
(Figure 3) was:
ISS
Ipeak
= B+
1− B
(1+ [L]IC50 )
nH
(3)
where ISS is the average steady state current at a given
concentration of agonist L, Ipeakis the corresponding peak
current,B is the minimal fractional steady state current, IC50 is
the concentration of L at which ISS/Ipeak = 0.5, and nH is the
Hill coefficient. ISS was found by fitting the current decay with
a single exponential function and taking the steady state value
of this function. A similar function was used to fit the fractional
inhibition in Figures 4B, 5B.
The function used to fit the concentration-response data
for nicotine at a given NNk concentration (Figure 5C; red
continuous line) was:
y =
αNic
[Nic]
EC50
+
αNNK [NNK]
EC50(NNK)
1+ [Nic]EC50 +
[NNK]
EC50(NNK)
(4)
where y is the fractional current in the presence of NNK plus
nicotine, αNicand αNNKare the maximal fractional responses
produced by nicotine and NNK, respectively (also named
intrinsic activities of the agonists; Hogg and Bertrand, 2007);
[Nic] and [NNK] are, respectively, the concentrations of nicotine
and NNK; EC50 and EC50(NNK) are, respectively, the EC50
values for nicotine and NNK. The model is simplified in that
it only considers single EC50’s for both the full and the partial
agonist.
Statistics
Data are given as mean values ± standard error of the mean,
with n indicating the number of determinations (i.e., the number
of cells tested). Statistical significance was determined with two-
tailed t-test for paired or unpaired samples, as appropriate, at
the indicated significance level (p). Normality was tested by the
Kolmogorov-Smirnov test.
Results
NNK Activates Human α4β2 nAChRs
We first tested if NNK can activate α4β2 nAChRs, by
applying the drug at −80mV. A representative example is
shown in Figure 2A. Consecutive applications of different NNK
concentrations were spaced 2–3min apart, to permit full recovery
from nAChR desensitization. NNK concentrations higher than
10 nM elicited inward currents, and the maximal effect was
obtained at 100µM NNK. Nicotine was usually applied at the
beginning and at the end of the experiment, to check for possible
current rundown. The concentration-response relation for NNK
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was obtained by plotting the average fractional peak currents
obtained at the indicated NNK concentrations (Figure 2B). On
average, the current elicited by 100µMNNK was approximately
14% of the current activated by saturating concentrations
of nicotine (300µM). No significantly higher currents were
observed when using 300µMNNK. For both nicotine and NNK,
data points were fitted with Equation 1, which gave apparent
EC50’s of approximately 28µM for nicotine and 17µM for
NNK. For all kinetic parameters, detailed statistics are given
in the figure legends, which also report the Hill coefficients.
For easier consulting, the main results are summarized in
Table 1.
The current activated by NNK was strongly blocked by 1µM
dihydro-β-erythroidine (DHβE), which is known to inhibit α4β2,
but not homomeric, nAChRs (Buisson et al., 1996; Alkondon
et al., 2000). To allow equilibration of DHβE concentration,
this compound was perfused in the bath for 30 s before the
agonist was added. To generate the data shown in Figure 2C,
the peak current measured in the presence of agonist plus
inhibitor was divided by the one elicited by the agonist alone.
These fractional residual currents were plotted for NNK (10µM),
nicotine (300µM), and ACh (300µM). DHβE blocked more
than 90% of the currents activated by either agonist, which is
consistent with our hypothesis that NNK specifically activated
the α4β2 nAChRs expressed in our cells.
A more detailed analysis of the concentration-response
relations for nicotine and NNK is shown in Figure 3. Best
fitting of the experimental data points was obtained by using the
two-terms Hill function (Equation 2). This is usually observed
with α4β2 nAChRs (Covernton and Connolly, 2000; Buisson
and Bertrand, 2001), and is attributed to the coexistence of
two receptor’s stoichiometries: (α4)3(β2)2 (with lower affinity)
and (α4)2(β2)3 receptors (with higher affinity; Nelson et al.,
2003). The fitting parameters were: EC50high = 0.035µM
and EC50low = 12.81µM, for NNK, and EC50high = 0.14µM
and EC50low = 7.7µM for nicotine. These results suggest
that NNK is particularly effective at stimulating the high
affinity nAChR component. Moreover, for both nicotine (e.g.,
Figure 5A) and NNK (e.g., Figure 2A), the activated current
displayed progressive desensitization in the presence of the
agonist. To quantify such process, the current decay was fitted
with a monoexponential function (e.g., Paradiso and Steinbach,
2003). Next, desensitization curves were generated by plotting
the average fractional steady state currents calculated from
the fitting procedure, for the indicated agonist concentration
(Figure 3). By using Equation 3 (continuous lines through
the data points), we estimated IC50 = 1.7µM for NNK,
and IC50 = 2.64µM for nicotine. In the absence of other
nicotinic ligands, the nAChR-dependent biological effect of NNK
must depend on the steady state current sustained by this
drug. This is proportional to the product of the activation
and desensitization curves (sometimes referred to as “window
current”), at a given NNK concentration. Figure 3 suggests that
the window currents of NNK and nicotine are broadly similar,
but that NNK tends to be comparatively more effective at the low
concentrations, in line with the range of plasma doses observed in
smokers.
FIGURE 2 | NNK, but not NNN, activates α4β2 nAChRs. (A) Consecutive
whole-cell current traces, elicited at -80mV by the indicated compound. Tests
were spaced 2–3min apart (gaps in the continuous current trace). Continuous
bars above the current traces indicate the time of agonist application. Nicotine
was repeatedly applied during the experiment to check for possible current
rundown. (B) Concentration-response relations for nicotine (black squares)
and NNK (red circles). Data points are average peak whole-cell currents
recorded at −80mV, normalized to the current elicited by 10µM nicotine and
plotted against the agonist concentration (in Log10 scale). Each point is the
average of at least seven determinations. The concentration-response relation
for nicotine (continuous line) and that for NNK (dashed line) were fitted with
Equation 1, which gave an EC50 = 27.8± 5.6µM (nH = 0.64) for nicotine and
16.7 ± 20µM (nH = 0.44) for NNK. The estimated maximal current activated
by NNK was approximately 16% of the current elicited by 300µM nicotine.
The measured peak current in the presence of 100µM NNK was 0.14 ± 0.02
(n = 13) of the value measured in the presence of 300µM nicotine. (C) DHβE
(1µM) strongly blocked the currents elicited by 300µM ACh, 300µM nicotine,
and 10µM NNK, as indicated. Data are averages of at least seven
determination for each condition, carried out at −80mV. Bars display the
fractional residual currents (i.e., the peak current measured in the presence of
the agonist plus DHβE divided by the peak current activated by the agonist
alone). In the presence of 10µM NNK, DHβE brought the average peak
current density (pA/pF) from 5.75 ± 1.22 to 0.53 ± 0.199 (p < 0.01 with
paired t-test; n = 9). (D) Comparison of the effects of NNN (10µM) and
nicotine (10µM) on whole-cell currents from α4β2 nAChRs, at −80mV. NNN
never produced nAChR activation in cells in which functional receptors were
shown to be present by nicotine application.
The Inhibitory Effect of NNN
Differently from NNK, NNN did not elicit any whole-cell
current even at concentrations (100µM)much higher than those
encountered in physiological conditions. Figure 2D shows a
typical experiment at−80mV, comparing the effects of 10µM
nicotine and 10µM NNN, in a cell expressing a large nicotinic
current. Once again, nicotine was applied before and after NNN,
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TABLE 1 | Comparison of the effects of nicotine, NNN, and NNK, on α4β2 nAChRs.
Compound Imax/Inico EC50 (µM) EC50high EC50low Desensitization IC50 (µM) Inhibition IC50 (µM)
(µM)
Nicotine 1 27.8 (nH = 0.65) 0.14 (nH1 = 1.1) 7.7 (nH2 = 2.1) 2.64 (nH = 1.8) N.A.
NNK 0.16 16.7 (nH = 0.44) 0.035(nH1 = 1.2) 12.81 (nH2 = 1.4) 1.7 (nH = 0.9) >100 (with 10µM nicotine)
NNN 0 N.A. N.A. N.A. 0.00021 (with 10µM nicotine)
FIGURE 3 | Activation and desensitization profiles for α4β2 nAChRs.
The activation curve for NNK (red circles) was generated by using experiments
analogous to those shown in Figure 2. The average peak current measured at
each concentration of NNK was normalized to the current elicited by 300µM
NNK. Data points are averages of at least seven determinations and were
fitted by using Equation 2 (continuous line), which gave EC50high = 0.035 ±
0.012µM (nH2 = 1.2), and EC50low = 12.81± 1.58µM (nH1 = 1.4). The
desensitization curve for NNK was generated by plotting average steady state
fractional currents (red triangles), as a function of NNK concentration. At each
concentration, the current decay in the presence of the drug was fitted with a
single exponential function. The steady state current values thus estimated
were divided by the corresponding peak current values. Data points are
averages of at least 6 determinations and were fitted by using Equation 3
(continuous line), which gave IC50 = 1.7µM ± 0.2 (nH = 0.9). The nicotine
activation (black circles) and desensitization (black triangles) curves were
obtained in a similar way. For activation, data points are averages of at least 6
determinations. They were fitted by using Equation 2 (continuous line), giving
EC50high = 0.14± 1.03µM (nH2 = 0.62), and EC50low = 7.7± 14.7µM
(nH1 = 1.8). For desensitization, data points were fitted with Equation 3
(continuous line), which gave IC50 = 2.64± 0.47µM (nH = 1.84).
to exclude channel rundown. Given that NNN produced no
nAChR activation, we studied its possible inhibitory effect in the
presence of nicotine. We tested NNN concentrations between
1 pM and 100µM on currents activated by concentrations of
nicotine ranging between 10 nM and 100µM. A representative
current trace is shown in Figure 4A, in which 10µM NNN
was applied in the presence of 10µM nicotine, at −80mV.
NNN was generally applied until the effect had reached the
steady state. Next, the drug was removed. After the current had
recovered from inhibition, nicotine was also washed out. This
experimental procedure (Buisson et al., 1996; Palma et al., 1996)
was preferred to the alternative procedure of pre-conditioning
with NNN and then applying simultaneously the agonist and
the antagonist (as we did with DHβE). The former method
allows to directly compare the effect of NNN with the one
produced by nicotine. In this way, the possible artifacts occurring
in repetitive consecutive trials (such as channel rundown, poor
solution exchange, precise estimation of the current peak, etc.)
are avoided or immediately recognized. Moreover, the blockade
kinetics can be directly appreciated. For each concentration, the
steady state current in the presence of NNN was divided by
the current remaining after NNN was removed. These fractional
currents were plotted in Figure 4B, as a function of the NNN
concentration, for the indicated nicotine concentrations (0.5,
10, and 100µM). Notice that higher nicotine concentrations
decreased the inhibitory effect of NNN, which suggests a
competitive blocking mechanism. For instance, the IC50 value for
NNN was >10µM in the presence of 100µM nicotine, whereas
it was approximately 1 nM in the presence of 10µM nicotine
(full statistics are reported in the figure legend). Conversely, the
concentration-response relations for nicotine in the presence of
the indicated NNN concentrations are plotted in Figure 4C. Data
points were fitted with Equation 1 (continuous lines through the
data points). The right-shift of the curves produced by NNN
is consistent with the notion that this drug tends to produce
competitive block of α4β2 nAChRs. From a pathological point of
view, it is worth noticing that NNN can exert significant current
block at concentrations normally encountered in smokers’
plasma (<100 pM; Schuller, 2007).
The Effect of NNK in the Presence of Nicotine
NNK is expected to produce effects more complex than those
shown by NNN, as partial agonists can produce channel
activation or inhibition depending on the concentration of
the full agonist (e.g., Hogg and Bertrand, 2007; Rollema
et al., 2007). In fact, concentrations of NNK up to 100 nM
produced no effect on the currents activated by 10µM nicotine,
whereas higher concentrations progressively inhibited α4β2
nAChRs (Figure 5A). These data were obtained and analyzed
as previously illustrated for NNN. Figure 5B plots the average
fractional residual currents measured in the presence of 10µM
nicotine, as a function of NNK concentration. Data points
were fitted with Equation 3 (continuous line), giving an
IC50 > 100µM. In contrast, the currents activated by low
concentrations of nicotine could be potentiated by NNK. An
example is given in the bottom panel of Figure 5A, showing that
100µMNNK increased the current activated by 100 nM nicotine
at −80mV, by approximately 80%. In agreement with the results
shown in Figure 3, the current activated by 100µM NNK also
displayed progressive desensitization. The effects of the tested
concentrations of NNK on the currents activated by different
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FIGURE 4 | NNN inhibits α4β2 nAChRs. (A) Typical whole-cell current
traces elicited by 10µM nicotine at −80mV, in the presence and in the
absence of 10µM NNN. Horizontal bars mark time of application of the
indicated compound. (B) Steady state inhibition curves were generated by
plotting the residual fractional steady state currents as a function of NNN
concentration (in Log10 scale). The different data sets were obtained at the
indicated concentration of nicotine. Data points are averages of at least nine
determinations. Lines through the data points are best fitting curves, obtained
with Equation 3. At 100µM nicotine, IC50 was > 20µM, whereas at 10µM
nicotine IC50 was 0.21 ± 0.4 nM. (C) Activation curves in the absence (black
squares) or in the presence of the indicated concentration of NNN. Data points
are peak whole-cell currents normalized to the current elicited by, 100µM
nicotine. Continuous lines through the data points are best fitting curves,
obtained with Equation 1. The corresponding parameters were: EC50 = 14.5
± 1.34µM (nH = 0.83), for nicotine alone; EC50 = 58.3± 4.4µM (nH = 0.92),
in the presence of 1 nM NNN; EC50 = 109.1± 0.14µM (nH = 1), in the
presence of 1µM NNN.
concentrations of nicotine are summarized in Figure 5C. For
comparison, the activation curve for nicotine (black circles) is
also reported. With 1µM NNK (red squares), the potentiation
produced on the currents activated by 0.01µMnicotine was 26%.
The concentration of nicotine at which the drug reversed its effect
was around 20 nM, as is estimated by fitting the data points with
the simplified model expressed by Equation 4 (continuous red
line). Saturating concentrations of NNK (100µM; red circles)
potentiated by about 80% the current activated by 0.1µM
nicotine, whereas they inhibited by 40% the current elicited by
10µM nicotine. In this case, the sign reversal of NNK effect
can be estimated to occur at approximately 400 nM nicotine. For
clarity, the error bars are not reported in Figure 5C. Instead,
the statistics of the current potentiation observed with NNK are
reported in detail in Figure 5D and in the figure legend. We
conclude that NNK, consistently with its partial agonist nature,
can produce either potentiation or inhibition of α4β2 nAChRs,
depending on the concomitant concentration of the full agonist.
The Block Produced by NNN and NNK was not
Voltage-dependent
The voltage dependence of the NNN and NNK effect is
illustrated in Figure 6. Current traces (Figure 6A) illustrate
typical experiments in which nAChRs were activated by 10µM
nicotine, at the indicated Vm. For briefness, only traces
obtained at −80mV (left) and +80mV (right) are shown.
NNN (10µM) was applied in the presence of nicotine and
removed after inhibition had reached the steady state. These
results are summarized in Figure 6B (top panel), showing the
current voltage relations in the presence of either nicotine
alone (Nico) or nicotine plus NNN (NNN). Data points are
average current values normalized to the absolute value of
the current measured at −80mV. The I/V plots displayed
the typical inward rectification of α4β2 nAChRs. Analogous
results were obtained with NNK (Figure 6C, top panel). The
apparent reversal potential (Vrev) was usually between +5 and
+20mV. The fractional block produced by either NNN or NNK
at the steady state was independent of the applied Vm. This
is better appreciated in the bottom panels of Figures 6B,C,
which give the average fractional residual currents as a function
of Vm, in the presence of NNN or NNK, respectively. The
data points around Vrev were removed as the small current
values prevented a reliable measure of the drugs’ effect. The
quick development and reversal of channel block suggests that
the effect was mainly caused by the nitrosamines accessing to
the channel from the extracellular milieu (i.e., we assume that
intracellular accumulation of the drugs was negligible). Hence,
because inhibition was virtually independent of the net direction
of ion flow, these nitrosamines are unlikely to exert significant
open channel block, at the concentrations we applied (much
higher than those observed in vivo).
Discussion
Comparison with Previous Studies
Binding of nitrosamines to nAChRs was previously studied
with radioactive ligand competition assays. These were mostly
carried out in lung cancer cell lines, by using labeled epibatidine
(to target heteromeric nAChRs) or α-bungarotoxin (specific
for α7; Schuller and Orloff, 1998; Schuller, 2007). Our results
qualitatively agree with these studies in that our nitrosamines
compete with the full agonist for binding to nAChRs. However, a
detailed quantitative comparison is difficult to draw. First, tumor
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FIGURE 5 | The effect of NNK on α4β2 nAChRs, in the presence of
nicotine. (A) Representative current traces elicited at −80mV by the indicated
concentration of nicotine (Nico), in the presence or in the absence of the
indicated concentration of NNK. The currents elicited by 10µM nicotine (top
and middle panels) are representative of 11 similar experiments. The bottom
panel illustrates the potentiating effect of 100µMNNK on the current activated
by 100 nM nicotine (representative of eight similar experiments). Bars mark the
time of application of nicotine and NNK, as indicated. (B)
Concentration-response relation for the inhibitory effect of NNK tested on
currents activated by 10µM nicotine, as illustrated in (A). Data points are
average steady state currents (n = 11) measured in the presence of a given
NNK concentration, divided by the current obtained after NNK was rinsed.
Continuous line through the data points is best fitting to Equation 3, giving IC50
> 100µM (nH = 0.95). (C) Summary of the effects of NNK plus nicotine. All data
are normalized to the current measured with 300µM nicotine. Black circles:
concentration-response for nicotine (same as in Figure 3; only concentrations
up to 100µM are shown). Red symbols: average fractional currents in the
presence of 1µM (squares), 10µM (triangles), or 100µM (squares) NNK, as a
function of [nicotine]. Data were obtained as illustrated in (A). The values
obtained with NNK were generally significantly different from those obtained
with nicotine alone. Detailed statistics for the potentiation data are given in (D).
The red continuous line is the curve best fitting the data points relative to 1µM
NNK, obtained by using Equation 4. The fit parameters were A = 1, B = 0.27,
[NNK]= 1µM, αNIC = 24µM, αNNK = 5µM. (D) The peak current measured in
the presence of 10 nM nicotine was 119 ± 24 pA, which was brought to 160 ±
30 pA by 1µMNNK (0.05 < p < 0.01, with t-test for paired samples; n = 11).
The effect of 100µMNNK was tested in a different series of cells, in which the
average current elicited by 100 nM nicotine was 89.4 ± 19.4 pA, which was
brought to 159.1 ± 25.1 pA by 100µMNNK (0.05 < p < 0.01, with t-test for
paired samples; n = 8). These results are plotted as black and red bars,
respectively for nicotine (Nico) and NNK. Statistical significance is indicated by *.
cell lines generally express multiple nAChR subtypes (Egleton
et al., 2008), and these have different pharmacological properties
(e.g., Dani and Bertrand, 2007). Second, electrophysiological
and binding analyses address different molecular features that
can be difficult to reconcile (e.g., Chang and Weiss, 1999). For
example, patch-clamp measurements reveal the population of
active channels, whereas the binding profile can be affected by
silent receptors, whose level of expression may be significant
(McNerney et al., 2000). Even with those qualifications, the EC50
we observed for NNK (Figure 3) with the single-term Hill model
is in good agreement with the one measured in binding studies
carried out on epibatidine-sensitive nAChRs (about 17µM, in
SCLC cells; Schuller, 2007). The highest binding efficacy of NNN
on α4β2 nAChRs is also in broad agreement with the binding
studies. The fact that NNN inhibited α4β2 nAChRs (Figure 4)
is consistent with the functional studies carried out on α3β4
receptors, although in the latter the affinity is lower and the
mechanism is mainly non-competitive (Nunes-Alves et al., 2012).
Based on our results and the absence of open channel block
(Figure 6), we hypothesize that the main site of nitrosamine
action on α4β2 nAChRs is close to the orthosteric binding site.
Functional Implications for Peripheral and
Cancer Tissue
Work on cell lines showed that nicotine and nitrosamines
produce similar effects, particularly stimulation of proliferation
and inhibition of apoptosis. In SCLC cells and gastrointestinal
cancer, the effects are mainly attributed to the activation of α7
receptors, whereas in other neoplastic cells, such as the NSCLC,
both homo- and heteromeric nAChRs contribute to the observed
effects (Schuller, 2009). In brief, nAChR activation tends to
stimulate exocytosis of autocrine factors (Cattaneo et al., 1993;
Jull et al., 2001) as well as other Ca2+-dependent pathways that
regulate proliferation and apoptosis (Schuller, 2009). The relative
contribution of the different nAChR subtypes is still debated.
One general working hypothesis is that, differently from α7
receptors, activation of heteromeric nAChRs stimulates pathways
that tend to suppress cancer progression (Schuller, 2009). If
this hypothesis is correct, our results suggest that NNN could
stimulate tumor progression by inhibiting the protective effects
contributed by heteromeric nAChRs, without affecting the less
sensitive α7. Alternatively, NNN might exert signaling roles not
depending on ion conduction (e.g., Dasgupta et al., 2006), or
activate other types of membrane receptors, or both. Evidence
is indeed available about the activation produced by NNK on β-
adrenergic receptors (Schuller et al., 1999), but not about NNN,
to the best of our knowledge.
The partial agonist nature of NNK makes it more difficult to
suggest a general interpretation of its cellular effects, particularly
because the direct effects of NNK on α7 nAChRs are currently
unknown. Considering that the binding studies indicate that
homomeric receptors are more sensitive to NNK, a reasonable
working hypothesis is that NNK induces both homo- and
heteromeric nAChR activation in cultured cells, and that the
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FIGURE 6 | The effects of NNN and NNK are not voltage-dependent. (A) Typical current traces obtained as illustrated in Figure 3, except that trials were carried
out at different Vm’s. For briefness, only the traces obtained at −80 and +80mV are displayed. Bars mark time of application of 10µM nicotine (Nico, continuous) and
10µM NNN (dashed). (B). Top panel: current-voltage relations obtained in the absence (squares) and in the presence (circles) of NNN. Data points are average steady
state current densities measured at the indicated Vm and normalized to the value obtained at -80mV (with a reversed sign, for consistency with the usual convention
of displaying inward current as negative). Data summarize the results of nine independent experiments. Continuous lines are polynomial curves best fitting the data
points. No correction was applied for junction potentials. Bottom panel: the fractional block produced by NNN is plotted as a function of Vm. Data points are average
steady state currents in the presence of NNN (INNN), divided by the current in the absence of NNN (INico). The data points around Vrev were omitted (see the main
text). No significant difference was observed among the results obtained at different Vm’s. (C) Top panel: same as in (C), for NNK (1µM, in the presence of 100 nM
nicotine). Bottom panel: the fractional block produced by NNK as a function of Vm was calculated as illustrated for NNN in (B), except that the tested Vm’s were:
−120/−80/−40/0/+40. Once again, no significant difference was observed among the results obtained at different Vm’s.
overall effect on Vm and calcium signals tends to prevail on
the tumor suppressing signals specifically induced by α4β2
activation.Moreover, although neither α7 (Kawai and Berg, 2001)
nor α4β2 (Buisson and Bertrand, 2001) receptors display long-
term inactivation in the presence of nicotine, the long-term
effects of nitrosamines on nicotinic currents are unknown.
Even more caution is necessary to interpret the effects of
the tobacco-related nitrosamines in vivo. We showed that the
typical concentrations of these compounds observed in vivo
can produce functional effects on α4β2 nAChRs. Smokers’
blood contain steady nitrosamine levels around 30–50 pM,
and the peak concentrations can be at least 10 times as high
(e.g., Hecht and Hoffmann, 1988; Schuller, 2007). In parallel,
smokers are exposed to widely fluctuating levels of plasma
nicotine, depending on smoking habits, not to speak of the
concomitant physiologically oscillating ACh levels depending on
parasympathetic activity. How nitrosamines and the full agonists
interfere in single individuals is difficult to predict, given that
the typical peak concentration of plasma nicotine in smokers
generally vary between 10 and 500 nM (e.g., Russell et al., 1980),
but can reach concentrations as high as 10µM, immediately after
smoking (Schaal and Chellappan, 2014). According to our results,
this wide range of concentrations allows both potentiating and
inhibiting effects of NNK, at least for α4β2 nAChRs. These
Frontiers in Pharmacology | www.frontiersin.org 8 September 2015 | Volume 6 | Article 201
Brusco et al. Nitrosamines modulate heteromeric nAChRs
observations may contribute to explain the individual variability
in the response to long-term smoking. In general, our study
points to the necessity of carrying out more extensive work
in vitro on the combined effects of nitrosamines and the full
agonists on specific nAChR subtypes.
Implication for Brain Pathophysiology
Because of their slow desensitization and high sensitivity to
ACh, α4β2 nAChRs are major regulators of the overall cerebral
excitability, as is also testified by the observation that the nAChR-
related epileptogenic mutations known to date are located on
genes coding for subunits of heteromeric receptors (Becchetti
et al., 2015). In the mammalian neocortex, heteromeric (largely
α4β2∗) nAChRs regulate excitatory (Vidal and Changeux, 1993;
Gioanni et al., 1999; Lambe et al., 2003; Disney et al., 2007; Zolles
et al., 2009; Poorthuis et al., 2012; Aracri et al., 2013) as well as
inhibitory (Xiang et al., 1998; Porter et al., 1999; Alkondon et al.,
2000; Couey et al., 2007; Aracri et al., 2010) neurotransmission
at both the pre- and post-synaptic level. These receptors also
regulate dopaminergic neurons, which bears implications for
tobacco addiction (Faure et al., 2014).
Interpreting the effects of nitrosamines in the brain requires
considering their tonic actions in resting conditions as well
as the phasic effects during transmitter release. The steady
concentration of nicotine in the cerebrospinal fluid of smokers is
close to the plasma levels (Berridge et al., 2010). Because the tonic
extracellular concentrations of ACh in the brain is thought to be
in the nanomolar range (Descarries et al., 1997), the steady effects
of nitrosamines in the brain likely compete mostly with nicotine,
whose levels depend on the smoking regimen. Considering that
α4β2 nAChRs display a higher affinity for NNN, and that the
latter tends to have a concentration higher than NNK, our results
suggest that the inhibitory effect of NNN should prevail, in steady
state conditions, irrespective of the nicotine level.
In contrast, in bona fide cholinergic synapses, on vesicle
release, the ACh concentration in the synaptic cleft quickly
reaches millimolar levels, thus activating the postsynaptic current
within hundreds of µs. The subsequent current decay displays
a kinetics that depends on tissue, largely because of the balance
between intrinsic nAChR desensitization and ACh removal
by acetylcholinesterase, but is generally complete within 5 to
20ms (e.g., Magleby and Stevens, 1972; Chu et al., 2000). Our
results (Figures 4B, 5B) suggest that the typical steady state
concentrations of nitrosamines normally observed in blood are
probably too low to affect classic postsynaptic currents activated
by high ACh levels. However, it is possible that long exposures to
nitrosamine compounds could affect the nAChR sensitivity and
expression.
Conclusions
The study of the interaction between nitrosamines and nAChRs
is still in its infancy. Our results show that NNK behaves as a
partial agonist of α4β2 nAChRs, whereas NNN is a receptor’s
inhibitor, with a relatively high affinity. In light of the above
discussion, these properties may explain at least in part the effects
produced by nitrosamines on neoplastic cell lines. However, to
reach a full biological interpretation of the nitrosamines’ roles in
vivo, including those in the CNS, further studies are needed along
the following lines. First, the effects of NNN and NNK should
be tested on other nAChR subtypes, particularly α7. Second,
whether nitrosamines induce long-term inactivation of nAChRs
should be also analyzed. Finally, it will be necessary to ascertain
the presence of different binding sites for these drugs on the
receptor’s protein.
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